(19)
(11) EP 2 768 513 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.05.2020 Bulletin 2020/21

(45) Mention of the grant of the patent:
25.12.2019 Bulletin 2019/52

(21) Application number: 12783158.4

(22) Date of filing: 18.10.2012
(51) International Patent Classification (IPC): 
A61K 31/7048(2006.01)
A61P 35/00(2006.01)
A61P 25/08(2006.01)
A61P 33/00(2006.01)
A61P 31/12(2006.01)
(86) International application number:
PCT/EP2012/070704
(87) International publication number:
WO 2013/057222 (25.04.2013 Gazette 2013/17)

(54)

USE OF AVERMECTIN DERIVATIVE FOR INCREASING BIOAVAILABILITY AND EFFICACY OF MACROCYLIC LACTONES

VERWENDUNG EINES AVERMECTINDERIVATS ZUR ERHÖHUNG DER BIOVERFÜGBARKEIT UND WIRKUNG VON MAKROCYCLISCHEN LACTONEN

UTILISATION D'UN DÉRIVÉ D'AVERMECTINE POUR AUGMENTER LA BIODISPONIBILITÉ ET L'EFFICACITÉ DES LACTONES MACROCYCLIQUES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.10.2011 EP 11306348

(43) Date of publication of application:
27.08.2014 Bulletin 2014/35

(60) Divisional application:
19215890.5

(73) Proprietors:
  • Institut national de recherche pour l'agriculture, l'alimentation et l'environnement
    75338 Paris Cedex 07 (FR)
  • The Royal Institution for the Advancement of Learning / McGill University
    Montréal, Québec H3A 2T5 (CA)

(72) Inventors:
  • LESPINE, Anne
    F-31000 Toulouse (FR)
  • PRICHARD, Roger
    F-31300 Toulouse (FR)
  • MENEZ, Cécile
    31 027 Toulouse Cedex 3 (FR)

(74) Representative: Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB 
Ganghoferstraße 68 B
80339 München
80339 München (DE)


(56) References cited: : 
EP-A1- 1 632 498
WO-A1-01/70028
   
  • SHERIFF J C ET AL: "Effects of macrocyclic lactone anthelmintics on feeding and pharyngeal pumping in Trichostrongylus colubriformis in vitro", PARASITOLOGY, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 125, no. 5, 1 November 2002 (2002-11-01), pages 477-484, XP009157239, ISSN: 0031-1820, DOI: 10.1017/S0031182002002251 [retrieved on 2003-01-17]
  • LESPINE A ET AL: "ABC transporter modulation: a strategy to enhance the activity of macrocyclic lactone anthelmintics", TRENDS IN PARASITOLOGY, ELSEVIER CURRENT TRENDS, GB, vol. 24, no. 7, 1 July 2008 (2008-07-01), pages 293-298, XP022763105, ISSN: 1471-4922, DOI: 10.1016/J.PT.2008.03.011 [retrieved on 2008-05-29]
  • LESPINE A ET AL: "Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)", CHEMICO-BIOLOGICAL INTERACTIONS, ELSEVIER SCIENCE IRLAND, IR, vol. 159, no. 3, 25 February 2006 (2006-02-25), pages 169-179, XP025058319, ISSN: 0009-2797, DOI: 10.1016/J.CBI.2005.11.002 [retrieved on 2006-02-25]
  • SHOOP W L ET AL: "Avermectins and milbemycins against Fasciola hepatica: In vivo drug efficacy and in vitro receptor binding", INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 25, no. 8, 1995, pages 923-927, XP002671288, ISSN: 0020-7519
  • MÁRTON JANI ET AL: "Ivermectin interacts with human ABCG2", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 100, no. 1, 1 January 2011 (2011-01-01), pages 94-97, XP055021665, ISSN: 0022-3549, DOI: 10.1002/jps.22262
  • FISHER M H ET AL: "The chemistry and pharmacology of avermectins.", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY 1992, vol. 32, 1992, pages 537-553, XP002688274, ISSN: 0362-1642
  • ASIO S M ET AL: "A randomised, double-blind field trial of ivermectin alone and in combination with albendazole for the treatment of Mansonella perstans infections in Uganda", TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, ELSEVIER, GB, vol. 103, no. 3, 1 March 2009 (2009-03-01) , pages 274-279, XP025917968, ISSN: 0035-9203, DOI: 10.1016/J.TRSTMH.2008.10.038 [retrieved on 2008-12-09]
  • TOWNSON S ET AL: "The effects of ivermectin used in combination with other known antiparasitic drugs on adult Onchocerca gutturosa and O. volvulus in vitro", TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, ELSEVIER, GB, vol. 84, no. 3, 1 May 1990 (1990-05-01), pages 411-416, XP023100877, ISSN: 0035-9203, DOI: 10.1016/0035-9203(90)90340-K [retrieved on 1990-05-01]
  • FURUSAWA SHINOBU ET AL: "Potentiation of doxorubicin-induced apoptosis of resistant mouse leukaemia cells by ivermectin", PHARMACY AND PHARMACOLOGY COMMUNICATIONS, LONDON, GB, vol. 6, no. 3, 1 March 2000 (2000-03-01), pages 129-134, XP009167795, ISSN: 1460-8081, DOI: 10.1211/146080800128735764 [retrieved on 2010-02-18]
  • SHENG-SHUNG PONG ET AL: "Studies on the Mechanism of Action of Avermectin B 1 a: Stimulation of Release of ?-Aminobutyric Acid from Brain Synaptosomes", JOURNAL OF NEUROCHEMISTRY, vol. 34, no. 2, 1 February 1980 (1980-02-01), pages 351-358, XP055060890, ISSN: 0022-3042, DOI: 10.1111/j.1471-4159.1980.tb06604.x
  • KOTZE A C: "Effects of macrocyclic lactones on ingestion in susceptible and resistant Haemonchus contortus larvae", THE JOURNAL OF PARASITOLOGY, AMERICAN SOCIETY OF PARASITOLOGISTS, US, vol. 84, no. 3, 1 June 1998 (1998-06-01), pages 631-635, XP008090959, ISSN: 0022-3395, DOI: 10.2307/3284740
  • DAWSON GERARD R ET AL: "Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acidA receptor", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 295, no. 3, December 2000 (2000-12), pages 1051-1060, XP002696207, ISSN: 0022-3565
  • DENG Y ET AL: "House fly head GABA-gated chloride channel: Toxicologically relevant binding site for avermectins coupled to site for ethynylbicycloorthobenzoate", PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY, ACADEMIC PRESS, US, vol. 43, no. 2, 1 June 1992 (1992-06-01), pages 116-122, XP024866990, ISSN: 0048-3575, DOI: 10.1016/0048-3575(92)90025-U [retrieved on 1992-06-01]
  • SHOOP W L ET AL: "Efficacy in sheep and pharmacokinetics in cattle that led to the selection of Eprinomectin as a topical endectocide for cattle", INTERNATIONAL JOURNAL OF PARASITOLOGY, PERGAMON PRESS, GB, vol. 26, no. 11, 1 January 1996 (1996-01-01), pages 1227-1235, XP002280645, ISSN: 0020-7519, DOI: 10.1016/S0020-7519(96)00122-1
  • DENHAM D A: "THE EFFECTS OF SOME AVERMECTINS ON THE GROWTH OF BRUGIA-PAHANGI", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 4, no. 5, 1982, pages 347-350, XP009169185, ISSN: 0379-0355
  • BANKS B J ET AL: "Avermectins and flea control: structure-activity relationships and the selection of selamectin for development as an endectocide for companion animals", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 8, no. 8, 1 August 2000 (2000-08-01), pages 2017-2025, XP027414349, ISSN: 0968-0896 [retrieved on 2000-08-01]
  • MICHAEL BRUCE ET AL: "Comparison of ivermectin, doramectin, selamectin, and eleven intermediates in a nematode larval development assay", THE JOURNAL OF PARASITOLOGY, AMERICAN SOCIETY OF PARASITOLOGISTS, US, vol. 87, no. 3, 1 June 2001 (2001-06-01), pages 692-696, XP009169206, ISSN: 0022-3395
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).